Skip to main content

Table 1 Baseline characteristics of patients

From: Oral beta-lactam step down in bacteremic E. coli urinary tract infections

  Oral fluoroquinolone step down (n = 130) Oral beta-lactam step down (n = 77) p-value
Age, median, years (IQR) 70.5 (56.25–80.75) 71 (54–80) 0.72
Sex    0.92
 Female 92 (71) 54 (70)  
 Male 38 (29) 23 (30)  
Comorbidities    
 Diabetes Mellitus 29 (22) 20 (26) 0.55
 Heart Conditions 75 (58) 43 (56) 0.8
 Chronic Kidney Disease 10 (8) 3 (4) 0.28
 Peripheral Vascular Disease 6 (5) 4 (5) 0.85
 Asthma or COPD 14 (11) 7 (9) 0.7
 Liver Cirrhosis 1 (1) 2 (3) 0.56
 Recurrent UTI Risk factors 38 (29) 22 (29) 0.92
 IVDU 5 (4) 0 (0) 0.16
 Hepatitis C 1 (1) 1 (1) 1.0
 HIV 0 (0) 0 (0) 1.0
 Immunocompromised 5 (4) 4 (5) 0.65
Charlson comorbidity index, median (IQR) 1 (0–2) 1 (0–3) 0.96
Catheter associated UTI 6 (5) 4 (5) 0.85
Hospital admission 101 (78) 62 (81) 0.63
ICU admission 9 (7) 5 (6) 0.91
Sepsis 31 (25) 25 (33) 0.2
Septic shock 8 (6) 5 (6) 0.92
Pitt bacteremia score, median (IQR) 0.5 (0–1) 1 (0–1) 0.53
Site of acquisition    0.02
 Community-acquired 110 (85) 53 (69)  
 Community-acquired health-care associated 15 (12) 20 (26)  
 Hospital-acquired 5 (4) 4 (5)  
Beta-lactam allergy 15 (12) 7 (9) 0.58
Inadequate empiric treatment 1 (1) 1 (1) 1.0
Stable at oral switch 125 (96) 74 (96) 0.99
Duration of intravenous treatment, median, days (IQR) 5 (3–7) 5 (3–7) 0.20
Duration of oral treatment, median, days (IQR) 7 (7–10) 7 (5.75–10) 0.38
Total treatment duration, median, days (IQR) 14 (12–14) 14 (11–14) 0.91
  1. Data are number (percentage) of patients unless otherwise indicated
  2. Abbreviations: COPD chronic obstructive pulmonary disease, ICU intensive care unit, IVDU intravenous drug use, UTI urinary tract infection;